NASDAQ:ARTL

Artelo Biosciences Q1 2025 Earnings Results & Report

Artelo Biosciences logo
$1.35 -0.10 (-6.97%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$1.37 +0.02 (+1.26%)
As of 11/20/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artelo Biosciences missed analyst earnings expectations in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$116.64 versus the -$21.06 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Artelo Biosciences EPS Results

Actual EPS
-$116.64
Consensus EPS
-$21.06
Beat/Miss
Missed by -$95.58
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 4 quarters

Artelo Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artelo Biosciences Q1 2025 Earnings FAQ

Artelo Biosciences (NASDAQ:ARTL) reported earnings of -$116.64 per share for Q1 2025, missing the consensus estimate of -$21.06. The report was announced on Tuesday, May 13, 2025.

Artelo Biosciences Earnings Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Artelo Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email.

About Artelo Biosciences

Artelo Biosciences (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company developing treatments that target the endocannabinoid system and related biological pathways. Its research focuses on potential therapies for conditions with significant unmet medical needs, including cancer-related symptoms and pain.

The company’s programs have included ART27.13, a cannabinoid receptor agonist being studied for cancer-related anorexia and cachexia, and ART26.12, a small-molecule inhibitor of fatty acid binding protein 5 under investigation for potential therapeutic applications. Artelo has also developed ART12.11, a cannabidiol-based cocrystal formulation.

Artelo is headquartered in the San Diego area of California. Its work is centered on drug research and development rather than the commercial sale of approved medicines.

View Artelo Biosciences Profile